Passage Bio
Edit info- Founded: 2019
- Location: Philadelphia, PA
- Employee range: 50 - 200
- Clinical stage: Clin1/Clin2
- Therapy area: GM1 Gangliosidosis
- Drug types: GEN, NEU, PED, RAR
- Lead product: PBGM01
- Funding: $154M stock Jan 2021; $248M IPO Feb 2020; $110M B Sep 2019; $115M A Feb 2019
- Investors: OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners, Vivo Capital, Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital, Sphera Funds Management
passagebio.comhome/default.aspx linkedin.com job board
Drug notes:
PBFT02 Clin1/Clin2 frontotemporal dementia; PBKR03 Clin1/Clin2 Krabbe disease; PBML04 Clin1/Clin2 metachromatic leukodystrophy; PBAL05 RD ALS; 2 undisclosed programs RD Huntington's disease, epilepsy
About:
Passage Bio is developing genetic medicines to treat rare disorders of the central nervous system. Drug development for neurodegenerative disorders has been challenging due to the blood brain barrier. Passage Bio’s solution is to create genetic drugs that are delivered directly into the cerebrospinal fluid, with the potential for long-term correction following a single treatment. Each genetic drug contains the functional therapeutic gene and the regulatory elements needed for the gene to be expressed. Passage Bio’s lead program is for people with frontotemporal dementia caused by a mutation in the GRN gene. The therapy involves delivering a functional GRN gene to elevate levels of progranulin in the brain.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com